ALKoma: a cancer subtype with a shared target.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic lymphoma kinase (ALK) is a protein tyrosine kinase implicated in oncogenesis.
• ALK alterations, including fusions (e.g., with NPM1, TPM3/4, EML4, VCL) and missense mutations, drive tumor formation in various cancers like lymphoma, lung, and thyroid cancers.
• The clinical efficacy of ALK inhibitors, such as crizotinib, has been demonstrated in certain ALK-driven malignancies.

Purpose of the Study:

• To propose a unifying term, "ALKoma," for tumors driven by aberrant Anaplastic Lymphoma Kinase (ALK).
• To highlight the common molecular driver (aberrant ALK) across diverse malignancies.
• To emphasize the therapeutic potential of targeting ALK in these collective tumor types.

Main Methods:

• Literature review of ALK's role in oncogenesis.
• Analysis of ALK fusion partners and mutation types across different cancers.
• Review of clinical data on ALK inhibitor efficacy.

Main Results:

• Identified multiple ALK fusion partners (NPM1, TPM3/4, EML4, VCL) and activating mutations (neuroblastoma, anaplastic thyroid cancer).
• Confirmed that these diverse tumors share activated ALK as a critical growth driver.
• Demonstrated significant clinical efficacy of ALK inhibitors in ALK-fusion positive tumors, with crizotinib approved for ALK-rearranged lung cancer.

Conclusions:

• Proposed "ALKoma" as a collective term for tumors with abnormal ALK as an essential growth driver.
• This classification emphasizes the shared oncogenic pathway and therapeutic target across distinct cancers.
• "ALKoma" facilitates a unified approach to understanding and treating these ALK-dependent malignancies.